La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

T2 Biosystems Gestione

Gestione criteri di controllo 4/4

T2 Biosystems' Il CEO è John Sperzel, nominato in Jan2020, e ha un mandato di 4.58 anni. la retribuzione annua totale è $ 865.50K, composta da 66.4% di stipendio e 33.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.002% delle azioni della società, per un valore di $ 1.50K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.6 anni e 7.5 anni.

Informazioni chiave

John Sperzel

Amministratore delegato

US$865.5k

Compenso totale

Percentuale dello stipendio del CEO	66.4%
Mandato del CEO	4.6yrs
Proprietà del CEO	0.002%
Durata media del management	5.6yrs
Durata media del Consiglio di amministrazione	7.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

Sep 22

T2 Biosystems' Survival Riddle

Aug 26

T2 Biosystems Q2 2022 Earnings Preview

Aug 12

T2 Biosystems drops 4% on Q2 guidance and 2022 outlook

Jul 06

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di John Sperzel rispetto agli utili di T2 Biosystems?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$48m
Mar 31 2024	n/a	n/a	-US$46m
Dec 31 2023	US$866k	US$575k	-US$50m
Sep 30 2023	n/a	n/a	-US$50m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$64m
Dec 31 2022	US$2m	US$575k	-US$62m
Sep 30 2022	n/a	n/a	-US$64m
Jun 30 2022	n/a	n/a	-US$61m
Mar 31 2022	n/a	n/a	-US$55m
Dec 31 2021	US$4m	US$563k	-US$49m
Sep 30 2021	n/a	n/a	-US$47m
Jun 30 2021	n/a	n/a	-US$44m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	US$3m	US$491k	-US$47m

Compensazione vs Mercato: La retribuzione totale di John ($USD 865.50K ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 681.57K ).

Compensazione vs guadagni: La retribuzione di John è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

John Sperzel (61 yo)

4.6yrs

Mandato

US$865,500

Compensazione

Mr. John J. Sperzel, III, B.Sc., serves as Chief Executive Officer and Director of T2 Biosystems, Inc. since January 8, 2020 and has been its Chairman since July 23, 2021 and serves as President. Mr. Sperz...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
John Sperzel	President	4.6yrs	US$865.50k	0.0023% $ 1.5k
John Sprague	Chief Financial Officer	6.6yrs	US$581.00k	0.00081% $ 529.5
Michael Gibbs	Senior VP	8.6yrs	US$622.60k	0.00077% $ 503.4
Kelley Morgan	Chief People Officer	10.4yrs	Nessun dato	Nessun dato
Brett Giffin	Chief Commercial Officer	2.8yrs	Nessun dato	0.00044% $ 287.7
Roger Smith	Senior Vice President of Science Research & Development	2.4yrs	Nessun dato	Nessun dato

5.6yrs

Durata media

60yo

Età media

Gestione esperta: Il team dirigenziale di TTOO è esperto e expertise (durata media dell'incarico 5.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
John Sperzel	President	4.6yrs	US$865.50k	0.0023% $ 1.5k
Robin Toft	Independent Director	4.2yrs	US$60.00k	0.00033% $ 215.7
Seymour E. Liebman	Independent Director	7.9yrs	US$40.00k	0.00049% $ 320.3
John Cumming	Lead Independent Director	10.1yrs	US$96.00k	0.00030% $ 196.1
David Elsbree	Independent Director	10.1yrs	US$60.00k	0.00045% $ 294.2
Eric Rosenberg	Member of Clinical Advisory Board	13.3yrs	Nessun dato	Nessun dato
Louis Rice	Member of Clinical Advisory Board	13.3yrs	Nessun dato	Nessun dato
Ninfa Saunders	Independent Director	4.2yrs	US$50.00k	0.00042% $ 274.6
Peter Pappas	Member of Clinical Advisory Board	13.3yrs	Nessun dato	Nessun dato
Michael Pfaller	Member of Clinical Advisory Board	7yrs	US$1.10m	Nessun dato
Laura Adams	Independent Director	2.8yrs	US$40.00k	0.00021% $ 137.3
Sean Zhang	Member of Scientific Advisory Board	2.3yrs	Nessun dato	Nessun dato

7.5yrs

Durata media

70yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di TTOO sono considerati esperti (durata media dell'incarico 7.5 anni).

T2 Biosystems Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors

Insufficient new directors

T2 Biosystems, Inc., Annual General Meeting, Sep 12, 2023

High number of new directors

T2 Biosystems, Inc. Announces Resignation of Alec Barclay as Chief Operations Officer, Effective November 30, 2022

T2 Biosystems, Inc., Annual General Meeting, Oct 11, 2022

Recent updates

T2 Biosystems, Inc. to Report Q2, 2024 Results on Jul 29, 2024

T2 Biosystems, Inc. has filed a Follow-on Equity Offering in the amount of $14.658742 million.

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements

T2 Biosystems, Inc. announced that it expects to receive $8.000002 million in funding

T2 Biosystems, Inc. announced that it expects to receive $8.000002 million in funding

T2 Biosystems, Inc. has withdrawn its Follow-on Equity Offering.

T2 Biosystems, Inc. to Report Q1, 2024 Results on May 06, 2024

T2 Biosystems, Inc. has filed a Follow-on Equity Offering.

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

T2 Biosystems Announces Agreement with CRG for Conversion of Term Loan into Equity to Regain Compliance

T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel

T2 Biosystems, Inc. to Report Q4, 2023 Results on Feb 15, 2024

T2 Biosystems Announces Participation in NIH-Funded Antibacterial Resistance Leadership Group (Arlg) Pilot Study for Pneumonia Patients

T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

The Nasdaq Listing Qualifications Staff Issues Delist Determination to T2 Biosystems

T2 Biosystems, Inc. announced delayed 10-Q filing

Insufficient new directors

T2 Biosystems, Inc. Highlights New Clinical Data Presented At IDWeek 2023 Conference

Consensus revenue estimates decrease by 21%, EPS upgraded

T2 Biosystems Provides Nasdaq Compliance Update

T2 Biosystems, Inc. to Report Q3, 2023 Results on Oct 12, 2023

T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel

Price target increased by 58% to US$0.15

T2 Biosystems, Inc. Updates Revenue Guidance for the Year 2023

T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement

T2 Biosystems Receives Extension through November 20, 2023 to Comply with Nasdaq's Minimum Bid Price and Market Value of Listed Securities Requirements

T2 Biosystems, Inc., Annual General Meeting, Sep 12, 2023

T2 Biosystems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

T2 Biosystems, Inc. Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems, Inc. Provides Revenue Guidance for the Year 2023

T2 Biosystems, Inc. announced that it has received $0.1 million in funding from CR Group L.P.

T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test

T2 Biosystems Receives Letter from Nasdaq Regarding its Shares Failure to Comply with the Market Value of Listed Securities Required for Continued Listing on The Nasdaq Capital Market

T2 Biosystems, Inc. announced delayed 10-Q filing

Insufficient Growth At T2 Biosystems, Inc. (NASDAQ:TTOO) Hampers Share Price

Full year 2022 earnings: EPS misses analyst expectations

Consensus revenue estimates decrease by 50%, EPS upgraded

T2 Biosystems, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

T2 Biosystems, Inc. has completed a Follow-on Equity Offering.

T2 Biosystems, Inc. Announces Positive Results Upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel

T2 Biosystems Inc. Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation's LymeX Diagnostics Prize

Consensus EPS estimates fall by 15%

Price target decreased to US$1.85

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

T2 Biosystems, Inc. Announces Resignation of Alec Barclay as Chief Operations Officer, Effective November 30, 2022

T2 Biosystems Regains Compliance with Nasdaq’s Minimum Bid Price Rule

T2 Biosystems, Inc. to Report Q3, 2022 Results on Nov 10, 2022

T2 Biosystems, Inc. Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel

T2 Biosystems, Inc. Announces Plan to Commercialize A Diagnostic Test for Early Lyme Disease

T2 Biosystems to develop, commercialize diagnostic test for early Lyme disease

T2 Biosystems, Inc. Updates Revenue Outlook for the Full Year of 2022

T2 Biosystems, Inc. Announces BARDA Exercise of Contract Option 3 Valued at $3.7 Million

T2 Biosystems announces BARDA exercise of contract option 3 valued at $3.7M

T2 Biosystems stock rises ~17% after hours on Baltic region distribution agreement

T2 Biosystems' Survival Riddle

T2 Biosystems, Inc., Annual General Meeting, Oct 11, 2022

T2 Biosystems, Inc. announced delayed 10-Q filing

T2 Biosystems Q2 2022 Earnings Preview

T2 Biosystems, Inc to Explore Potential to Develop Rapid Molecular Diagnostic Test for Monkeypox Virus

T2 Biosystems, Inc. to Report Q2, 2022 Results on Aug 15, 2022

T2 Biosystems Receives Non-Compliance Notice from Nasdaq

T2 Biosystems, Inc. Receives Food and Drug Administration Breakthrough Device Designation for the T2Lyme Panel

Consensus forecasts updated

T2 Biosystems, Inc. Provides Preliminary Unaudited Revenue Guidance for the Quarter Ended June 30, 2022 and Provides Revenue Guidance for the Full Year 2022

T2 Biosystems drops 4% on Q2 guidance and 2022 outlook